Health Care · Pharmaceutical Preparations

DSGN Design Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 180712058 filings
Russell 2000

DSGN at a glance

Design Therapeutics, Inc. (DSGN, SEC CIK 1807120) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as June 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Design Therapeutics, Inc. (DSGN) reported revenue of $0 and a net loss of $69.8 million. Diluted EPS was -$1.22.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Design Therapeutics, Inc. (DSGN) shares worth $128.0 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
10-K XBRL
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
24 funds
$128.0M · −3 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added trade-policy risk: 2025 tariffs and potential sanctions threaten foreign API supplies, increasing development costs and disrupting clinical timelines
  • Most materially updated manufacturing risk: BIOSECURE Act restrictions could limit use of Chinese biotechnology suppliers after the mid-December 2026 designation list
  • Regulatory risk: Loper Bright decision increases challenges to FDA rules and uncertainty around agency interpretations
  • Near-term clinical risk: omaveloxolone availability may reduce FA trial enrollment for DT-216P2
  • Financial risk: $208.6 million in cash, equivalents and investments funds operations over 12 months but not regulatory approval or commercialization

Management Discussion & Analysis

  • Product revenue $0, unchanged YoY, no approved products or product sales
  • Operating expenses $22.2M vs $19.3M YoY, research and development $16.9M vs $14.6M
  • Best program: DM1 R&D $3.3M, up from $0; worst: FECD $1.6M vs $(1.1)M
  • Cash, equivalents and investments $208.6M, down $11.2M from December 31, 2025
  • Operating cash use $47.3M; ATM financing $37.1M, runway more than 12 months

AI summary of the DSGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Design Therapeutics’ financial results for the three and nine months ended September 30, 2026
  • Exhibit 99.1 contains the detailed financial results and management commentary for investor review

Item EX-99.1: Item EX-99.1

  • Q3 2026 net loss $20.3M, or $0.32 per share, versus $17.0M and $0.30 in Q3 2025
  • R&D spending rose to $16.9M from $14.6M, reflecting increased clinical development investment
Filed Aug 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Design Therapeutics reported financial results for Q2 and six months ended June 30, 2026
  • Results detailed in Exhibit 99.1, the company’s accompanying earnings press release

Item EX-99.1: Item EX-99.1

  • Q2 net loss $20.2M, or $0.32 per share, with R&D spending of $16.4M
  • Cash and securities $207.4M at June 30, down from $219.8M at December 31
Filed Jun 11, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Simeon George, M.D. elected Class II director through 2029 annual meeting
  • Director vote: 29,205,208 for, 7,608,724 withheld, 13,264,883 broker non-votes

AI summaries of DSGN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for DSGN

Don't miss the next DSGN filing

  • Alerts as it files. A push when DSGN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut DSGN, by share count.
  • Ask anything. An AI agent that reads every DSGN filing and answers with sources.

DSGN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Schmid John P.AJun 9, 2026-
Berger Heather A.AJun 9, 2026-
Gover Justin D.AJun 9, 2026-
LAPPE RODNEY WAJun 9, 2026-
Shapiro DavidAJun 9, 2026-
George SimeonAJun 9, 2026-
Shapiro DavidAMar 31, 2026-
Shapiro DavidAMar 31, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$0$0
Operating Income-$78.2M-$62.4M-$79.5M
Net Income-$66.9M-$49.6M-$69.8M
Balance Sheet
Total Assets-$252.1M$226.2M
Equity$277.7M$242.1M$212.5M
ROE-24.1%-20.5%-32.8%
Per Share
EPS-$-0.88$-1.22
Cash Flow
Operating CF-$58.6M-$43.1M-$54.4M
CapEx-$340K$193K

Source: XBRL data in Design Therapeutics, Inc. (DSGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate DSGN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
DSGN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$128.0M
Q2 202627$145.5M
Q1 202627$92.7M
Q4 202525$83.9M
Q3 202523$56.3M
Q2 202522$28.8M
Q1 202521$24.7M
Q4 202416$36.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 185 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

DSGN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
SC 13GAug 14, 2026-
10-QAug 3, 2026Analysis
8-KAug 3, 2026Analysis-
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
8-KJun 11, 2026Analysis-
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
SC 13GJun 9, 2026-
8-KMay 18, 2026Analysis
8-KApr 28, 2026Analysis-
10-QApr 28, 2026Analysis
8-KApr 1, 2026--
4Apr 1, 2026--
10-KMar 9, 2026-
8-KMar 9, 2026Analysis-
8-KJan 30, 2026-
4Jan 5, 2026-
4Jan 5, 2026-
4Jan 5, 2026-
4Jan 5, 2026-

Related Health Care companies

All Health Care →

DSGN SEC filings: frequently asked questions

Which institutions hold DSGN stock?

As of September 30, 2026, the largest Design Therapeutics, Inc. (DSGN) holders among the 13F filers tracked by SignalX were BlackRock ($34.1 million), State Street Corp ($21.0 million), Vanguard Capital Management LLC ($21.0 million), Dimensional Fund Advisors ($9.1 million), Morgan Stanley ($8.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was DSGN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Design Therapeutics, Inc. (DSGN) reported revenue of $0 and a net loss of $69.8 million. Diluted EPS was -$1.22. The figures come from the XBRL data in the 10-K.

What did DSGN report in its latest 8-K?

Design Therapeutics, Inc. (DSGN) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Design Therapeutics’ financial results for the three and nine months ended September 30, 2026.

What are the latest DSGN SEC filings?

Design Therapeutics, Inc. (DSGN) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on June 11, 2026.

What is DSGN's SEC CIK number?

Design Therapeutics, Inc. (DSGN)'s SEC Central Index Key (CIK) is 1807120. EDGAR lists every DSGN filing under that number.

Ask anything about DSGN

The research agent reads DSGN's filings, financials, insider trades and 13F holders, then answers with sources.